Omega-3s that help immune cells calm dust-related lung inflammation

Omega-3 fatty acids induce macrophage IL-22 signaling to promote resolution of dust-induced lung inflammation

NIH-funded research University of Nebraska Medical Center · NIH-11394758

This project looks at whether omega-3 fats and their natural products can switch on lung immune signals to help people with dust-related airway inflammation heal better.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Nebraska Medical Center NIH-funded
Lab location1 site (Omaha, United States)
Project IDNIH-11394758 on NIH RePORTER

What this research studies

This project examines how omega-3 fats like DHA and a related molecule called maresin-1 activate IL-22 signaling in lung macrophages. Researchers use laboratory studies with lung cells and animal models of repeated dust inhalation to see how these signals affect airway inflammation and repair. They will measure immune responses, epithelial barrier health, and levels of pro-resolving lipids to understand the protective mechanism. Findings will be compared to human lung biology where possible to guide future patient-focused trials.

Who could benefit from this research

Good fit: People with airway inflammation from repeated dust exposures — for example farmers, agricultural workers, or others with dust-related chronic bronchitis or similar conditions — would be the most relevant candidates for future trials based on this work.

Not a fit: Patients whose lung problems are primarily due to infections, genetic or structural lung disease, or causes unrelated to dust-driven inflammation may not benefit from interventions targeting this pathway.

Why it matters

Potential benefit: If successful, this work could point to dietary or drug strategies using omega-3–derived molecules to reduce dust-related airway inflammation and improve lung healing.

How similar studies have performed: Previous lab and animal studies have shown omega-3s and specialized pro-resolving mediators can reduce lung inflammation, but activating IL-22 in macrophages is a new finding and human benefits remain unproven.

Where this research is happening

Omaha, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Airway DiseaseDiseaseDisorder
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.